EagleClaw Capital Managment LLC Sells 3,800 Shares of InMode Ltd. (NASDAQ:INMD)

EagleClaw Capital Managment LLC cut its stake in InMode Ltd. (NASDAQ:INMD) by 17.4% in the 3rd quarter, Holdings Channel reports. The firm owned 18,000 shares of the healthcare company’s stock after selling 3,800 shares during the period. EagleClaw Capital Managment LLC’s holdings in InMode were worth $305,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of INMD. Renaissance Technologies LLC boosted its stake in shares of InMode by 11.6% in the 2nd quarter. Renaissance Technologies LLC now owns 2,068,396 shares of the healthcare company’s stock worth $37,728,000 after buying an additional 214,200 shares during the last quarter. Doma Perpetual Capital Management LLC raised its position in InMode by 210.7% in the 2nd quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company’s stock worth $36,685,000 after purchasing an additional 1,363,841 shares during the period. DDD Partners LLC grew its stake in InMode by 19.4% in the 2nd quarter. DDD Partners LLC now owns 1,266,678 shares of the healthcare company’s stock worth $23,104,000 after acquiring an additional 205,947 shares in the last quarter. Federated Hermes Inc. increased its position in InMode by 191.9% during the 2nd quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company’s stock valued at $20,520,000 after purchasing an additional 739,629 shares during the period. Finally, Acadian Asset Management LLC increased its holdings in shares of InMode by 63.6% during the second quarter. Acadian Asset Management LLC now owns 1,124,887 shares of the healthcare company’s stock valued at $20,502,000 after acquiring an additional 437,122 shares in the last quarter. Institutional investors own 68.04% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on INMD. Barclays lowered their price objective on InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a research report on Monday, October 14th. Jefferies Financial Group cut shares of InMode from a “buy” rating to a “hold” rating and dropped their price objective for the company from $21.00 to $19.00 in a research note on Tuesday, July 23rd. BTIG Research started coverage on shares of InMode in a research report on Thursday, October 17th. They set a “buy” rating and a $25.00 price objective for the company. Finally, Needham & Company LLC restated a “hold” rating on shares of InMode in a report on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, InMode currently has a consensus rating of “Hold” and a consensus price target of $22.60.

InMode Trading Down 0.1 %

Shares of InMode stock traded down $0.02 during trading on Wednesday, reaching $17.69. The company’s stock had a trading volume of 62,019 shares, compared to its average volume of 1,333,285. The company has a 50-day moving average price of $17.30 and a two-hundred day moving average price of $17.46. The firm has a market cap of $1.49 billion, a PE ratio of 9.57 and a beta of 2.15. InMode Ltd. has a fifty-two week low of $14.87 and a fifty-two week high of $26.80.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.